Format

Send to

Choose Destination
Hum Vaccin Immunother. 2016 Nov;12(11):2902-2908.

Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.

Author information

1
a Division of Infectious Diseases, Department of Internal Medicine , Korea University College of Medicine , Seoul , Korea.
2
b Asia Pacific Influenza Institute, Korea University College of Medicine , Seoul , Korea.
3
c Division of Infectious Diseases, Department of Internal Medicine , Hallym University College of Medicine , Chuncheon , Korea.
4
d Division of Nephrology, Department of Internal Medicine , Korea University College of Medicine , Seoul , Korea.
5
e Division of Nephrology, Department of Internal Medicine , Hallym University College of Medicine , Chuncheon , Korea.

Abstract

BACKGROUNDS:

Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD).

METHODS:

During 2013-2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured.

RESULTS:

The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03).

CONCLUSION:

The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.

KEYWORDS:

MF59 oil emulsion; influenza vaccines; renal dialysis

PMID:
27802078
PMCID:
PMC5137514
DOI:
10.1080/21645515.2016.1191717
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center